An antibody that has the power to neutralise any influenza strain could be widely administered in the form of a nasal spray ...

Company highlights accelerating access and revenue growth for ARBLI and confirms REZENOPY launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Ou ...

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual ...

ETHealthworld.com brings latest nasal spray news, views and updates from all top sources for the Indian Health industry.

A few months after sending an untitled letter to ARS Pharmaceuticals, taking issue with certain aspects of a TV commercial about its epinephrine nasal spray, the FDA is reiterating its concerns about ...

Milestone Pharmaceuticals (MIST) announced that cardamyst nasal spray, its first commercial product, is now available through U.S. retail pharmacies. Cardamyst is a prescription medication indicated ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...

Special Report: The first patients have been dosed in LTR Pharma’s Phase II pharmacokinetic clinical study of SPONTAN, its rapid-acting intranasal spray for the treatment of erectile dysfunction (ED).

REZENOPY ™ received approval from the U.S. Food and Drug Administration (the “FDA”) on April 19, 2024. The newly issued patent is eligible for listing in the FDA’s Orange Book and, if listed, may ...